文献速递免疫规划卫生政策与健康促进

新型冠状病毒初次同源疫苗接种或首次感染后保护持续时间

Duration of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after primary homologous vaccination or first infection.
PubMed 文献 · Vaccine · 2025-07-04

该回顾性队列研究在克罗地亚奥西耶克-巴拉尼亚县分析119,596名受试者,用生存分析评估初次疫苗接种或首次SARS-CoV-2感染后95%人群的保护持续时间。首次感染后95%人群保护持续256天(CI 251-264),同源初次接种以Spikevax最长,为143天(CI 133-150);感染后保护均长于任何疫苗初次接种。

要点

  • 首次感染后95%人群保护持续256天(CI 251-264),90%人群为365天(CI 350-381)。
  • 同源初次接种95%人群保护:Spikevax 143天(CI 133-150),Comirnaty 119天(CI 116-122),Jcovden 77天(CI 71-84),Vaxzevria 125天(CI 118-131)。
  • 感染后保护持续时间长于任何同源疫苗初次接种,再接种间隔平均为初次接种保护的两倍。

核心结论

  • SARS-CoV-2感染后保护持续时间长于任何同源疫苗初次接种,再接种间隔平均为初次接种保护的两倍。

研究设计与样本

  • 研究为在克罗地亚奥西耶克-巴拉尼亚县开展的回顾性队列研究,时间范围为2020年12月27日至2023年5月12日。
  • 共分析119,596名受试者,涵盖男女两性及所有年龄组,采用生存分析方法。

主要发现

  • 首次感染后95%人群保护持续256天(CI 251-264),90%人群为365天(CI 350-381)。
  • 同源初次接种Spikevax后95%和90%人群保护分别持续143天(CI 133-150)和192天(CI 183-201)。
  • 同源初次接种Comirnaty后95%和90%人群保护分别持续119天(CI 116-122)和168天(CI 165-170)。
  • 同源初次接种Jcovden后95%和90%人群保护分别持续77天(CI 71-84)和164天(CI 154-172)。
  • 同源初次接种Vaxzevria后95%和90%人群保护分别持续125天(CI 118-131)和149天(CI 144-154)。

临床怎么用

  • 作者认为研究结论与制定再接种时机的公共卫生措施相关。
  • 作者报告既往感染SARS-CoV-2者再接种间隔平均为任何同源疫苗初次接种保护持续时间的两倍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to determine the duration of protection in 95 % of the population after primary vaccination (PV) and/or acquiring SARS-CoV-2 infection in order to make public health decisions. A study was a retrospective cohort study conducted in Osijek-Baranja County, Croatia, between December 27, 2020, and May 12, 2023. A total of 119,596 subjects of both sexes and all age groups were analyzed. The method of survival analysis was used. The length of protection (LoP) for 95 % and 90 % of the population with first infection was 256 (confidence interval (CI) 251-264) days and 365 (CI 350-381) days, respectively. In those primarily vaccinated, the longest duration of protection was recorded in subjects having received primary homologous vaccination with Spikevax (Moderna), 143 (CI 133-150) and 192 (CI 183-201) days, followed by those with Comirnaty (BioNTech/Pfizer), 119 (CI 116-122) and 168 (CI 165-170) days, respectively. The respective duration of protection was 77 (71-84) and 164 (154-172) days for Jcovden (Janssen-Cilag), and 125 (118-131) and 149 (144-154) days for Vaxzevria (AstraZeneca). Protection after SARS-CoV-2 infection was longest as compared with the LoP following primary vaccination with any of the vaccines. The interval for vaccination of the general population previously infected with SARS-CoV-2 is on average twice the protection provided by primary vaccination with any homologous vaccine. Conclusions based on the study results are relevant for making public health measures concerning re-vaccination timing.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mihin Huskić I, Benšić M, Kretonić K, et al. Duration of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after primary homologous vaccination or first infection. Vaccine. 2025. PMID: 40617090. doi:10.1016/j.vaccine.2025.127440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。